Table 1.
Clinical and pathological characteristics of the patients
| Pathology | Cases | N | Gleason Score | N | Age Average | ±SD | Range | tPSA ng/ml | ±SD | Range | fPSA ng/ml | ±SD | Range |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPH | 29 | 29 | 63.24 | 8.08 | 44-76 | 9.76 | 3.05 | 5.53-18.20 | 1.72 | 0.75 | 0.31-3.06 | ||
| PCa N=44 | Low risk | 5 | Gleason 6 | 5 | 67 | 5.34 | 61-74 | 6.91 | 1.10 | 5.22-8.29 | 1.16 | 0.23 | 0.96-1.50 |
| Intermediate risk | 17 | Gleason 6 | 8 | 59 | 9.49 | 47-75 | 7.79 | 3.76 | 5.10-16.40 | 0.92 | 0.50 | 0.27-1.70 | |
| Gleason 7 | 8 | 66.5 | 4.44 | 58-73 | 9.79 | 3.77 | 6.96-17.63 | 0.93 | 0.49 | 0.36-1.98 | |||
| Gleason 8 focal | 1 | 70 | 8.55 | 2.17 | |||||||||
| High risk | 22 | Gleason 7 / metastasis | 3 | 78.3 | 8.10 | 69-83 | 15.13 | 4.39 | 12.42-20.2 | 2.72 | 1.50 | 1.00-3.73 | |
| Gleason 8 | 8 | 61.6 | 10.89 | 51-81 | 24.42 | 15.38 | 4.14-54.12 | 2.17 | 1.95 | 1.04-6.81 | |||
| Gleason 9 | 8 | 71 | 9.77 | 51-79 | 28.55 | 33.35 | 6.48-109.7 | 4.56 | 4.93 | 0.19-15.20 | |||
| Gleason 10 | 1 | 49 | 15.07 | 3.39 | |||||||||
| Gleason ND* / metastasis | 2 | 75 | 11.31 | 67-83 | 10.03 | 1.85 | 8.72-11.33 | 1.84 | 1.13 | 1.04-2.64 |
*ND: non determined